scispace - formally typeset
Journal ArticleDOI

Risk Factors and Prognostic Factors of Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma

TLDR
This study demonstrated that tumor size > 2.5 cm was the main risk factor for local recurrence after RFA of hepatocellular carcinoma, and suggested that additional aggressive treatment ofLocal recurrence aimed at complete tumor response improves overall survival of patients.
Abstract
Background Local recurrence rates after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) vary from 2% to 36% in the literature. Limited data were available about the prognostic significance of local recurrence. Study Design Between April 2001 and March 2006, 273 patients with 357 hepatocellular carcinoma nodules underwent RFA, with radiologically complete tumor ablation after a single session of RFA. The risk factors of local recurrence and its impact on overall survival of patients were analyzed. Results With a median followup period of 24 months, local recurrence occurred in 35 patients (12.8%). By multivariate analysis, tumor size > 2.5 cm was the only independent risk factor for local recurrence. There was no notable difference in overall survival between patients with and without local recurrence. By multivariate analysis, local recurrence more than 12 months after RFA and complete response after additional treatment of local recurrence were associated with better overall survival in patients with local recurrence. Conclusions This study demonstrated that tumor size > 2.5 cm was the main risk factor for local recurrence after RFA of hepatocellular carcinoma. Our data suggested that additional aggressive treatment of local recurrence aimed at complete tumor response improves overall survival of patients. Late local recurrence was also associated with better prognosis, suggesting different tumor biology between early and late local recurrent tumors after RFA.

read more

Citations
More filters
Journal ArticleDOI

Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.

TL;DR: RFA is a safe and effective first‐line treatment of HCC up to 5 cm in diameter, especially for patients with a single tumor, a low serum AFP level, and well‐preserved liver function.
Journal ArticleDOI

Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors

TL;DR: Ten-year survival outcomes after percutaneous radiofrequency ablation as a first-line therapy of hepatocellular carcinoma were excellent despite frequent tumor recurrences, and overall survival was influenced by age, Child-Pugh class, antiviral therapy, or extrahepatic recurrence.
Journal ArticleDOI

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

TL;DR: In this paper, the authors analyse data from randomized and uncontrolled studies reported with ablative and locoregional techniques and examine the expected effects of combinations with systemic treatments, and discuss trial design and benchmarks to be used as a reference for future investigations in a promising new era for HCC treatment.
Journal ArticleDOI

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

TL;DR: Percutaneous ablation could also be used as a bridge to liver transplantation or in a sequence of upfront percutaneous treatment, followed by transplantation if the patient relapses, and several innovations in ablation methods may help to efficiently treat early HCC.
References
More filters
Journal ArticleDOI

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

TL;DR: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment.
Journal ArticleDOI

Rising incidence of hepatocellular carcinoma in the United States.

TL;DR: The incidence of hepatocellular carcinoma increased significantly among younger persons (40 to 60 years old) during the period from 1991 to 1995 as compared with earlier periods, and the age-specific incidence of this cancer has progressively shifted toward younger people.
Journal ArticleDOI

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

TL;DR: In Asian patients with unresectable hepatocellular carcinoma, transarterial Lipiodol chemoembolization significantly improves survival and is an effective form of treatment.
Journal ArticleDOI

A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma

TL;DR: PLAT was as effective as surgical resection in the treatment of solitary and small HCC and had the advantage over surgical resections in being less invasive.
Journal ArticleDOI

Small Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation versus Ethanol Injection

TL;DR: RF ablation results in a higher rate of complete necrosis and requires fewer treatment sessions than percutaneous ethanol injection, however, the complication rate is higher with RF ablation than with percutaneously ethanol injection.
Related Papers (5)